EMEA-001071-PIP02-12-M02
Key facts
Invented name |
Cimzia
|
Active substance |
Certolizumab pegol
|
Therapeutic area |
Immunology-Rheumatology-Transplantation
|
Decision number |
P/0192/2017
|
PIP number |
EMEA-001071-PIP02-12-M02
|
Pharmaceutical form(s) |
Solution for injection
|
Condition(s) / indication(s) |
Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis)
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
UCB Pharma S.A.
E-mail: ucbcares.uk@ucb.com |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|